Does SPRINT change our approach to blood pressure targets?

Therapeutics Letter #82 summarized evidence from the Cochrane systematic review, *Treatment blood pressure targets for hypertension.* The Cochrane review was based on the 7 randomized controlled trials (RCTs) designed to test treatment targets that were available as of October 2008. The conclusion was that “Treating patients to lower than standard blood pressure (BP) targets (≤ 140-160/90-100 mmHg) does not reduce mortality or morbidity.”

**SPRINT**

In September 2015, Systolic blood PRessure INtervention Trial (SPRINT) added a new trial that studied BP targets. It was stopped early for benefit. Results were published in November 2015. SPRINT randomly assigned 9361 persons with a systolic BP of 130 mmHg or higher and an increased cardiovascular risk (but without diabetes or prior stroke) to a low systolic BP target of < 120 mmHg or a standard target of < 140 mmHg. SPRINT was an open label trial conducted at 102 sites. The average achieved BP at one year in the low BP target group was 121/69 versus 136/76 mmHg in the standard BP target group. The average number of antihypertensive drugs in the low BP target group was 2.8, vs. 1.8 in the standard BP target group.

**Benefits**

After an average duration of 3.3 years, the primary outcome (a composite of myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes) was decreased in the low BP target group at 5.2%, vs. 6.8% in the standard BP target group, RR 0.76 [0.65, 0.90], ARR 1.6%, NNT 63 for 3.3 years.

**Harms**

Specific serious adverse events classified as possibly or definitely related to the intervention were increased in the low BP target group, 4.7%, vs. 2.5% in the standard BP target group, RR 1.87 [1.50, 2.33] ARI 2.2%, NNTH 46 for 3.3 years. This was due mainly to a 1.2% absolute increase in acute kidney injury or acute renal failure in the low BP target group.

**Overall effect**

Total serious adverse events were appropriately defined as fatal or life-threatening events resulting in clinically significant or persistent disability, or events that required or prolonged a hospitalization. The number of people with one or more serious adverse events was numerically greater in the low BP target group at 38.3% vs. 37.1% in the standard BP target group, RR 1.03 [0.98, 1.09]. However, deaths were significantly lower in the low BP target group at 3.3%, vs. 4.5% in the standard BP target group, RR 0.74 [0.60, 0.91], ARR 1.2%. These two findings are hard to reconcile, insofar as this means the number of people with non-fatal serious adverse events was significantly greater in the low BP target group, at 35.0% vs. 32.6% in the standard BP target group, RR 1.07 [1.02, 1.14], ARI 2.4%.

**Risk of bias**

Because of the BP target design, investigators could not be blinded to treatment group. This results in a high risk of performance and detection bias. Performance bias means the people caring for the patients treat the lower BP target group preferentially. Detection bias means investigators ascertain the outcomes in favour of the lower target group. Evidence of such bias in SPRINT is that the observed mean BP difference between the two groups of 15/7 mmHg is much greater than expected from a mean difference of one antihypertensive drug (2.8 vs. 1.8) between the target groups. The average BP reduction produced by a single antihypertensive drug has been studied extensively and estimated at about 8/5 mmHg.
Stopping the trial early for benefit also adds additional risk of bias in favour of the lower BP target. This action would tend to exaggerate the benefits and underestimate the harms outlined above. We judge that the outcomes least susceptible to bias is the total serious adverse events (SAE), because investigators presently do not recognize this outcome as an important way to assess the benefits and harms of an intervention.

**Clinical implications of SPRINT**
Most of the editorials and commentaries about the SPRINT trial have given it a positive spin and recommended that target BP should be lower as a result of this trial. These commentaries have ignored the finding that individuals experiencing at least one serious adverse event were numerically increased in the low BP target group. None of these commentaries have situated SPRINT into the totality of available evidence on BP lowering targets.

**Systematic review**
The relevant Cochrane review has the objective: To determine if there is a reduction in total mortality and morbidity associated with treatment of blood pressure to “lower targets” (≤ 135/85 mmHg) as compared with “standard targets” (≤ 140-160/90-100 mmHg) in the management of patients with elevated arterial blood pressure. First published in 2009, it is now being updated. In addition to SPRINT, two large trials, ACCORD and SPS3 have been added to the review. In the updated review, mortality data from 11 RCTs (N = 38,584) indicate that lower targets do not reduce total mortality; RR 0.95 [0.86, 1.05].

Furthermore, this analysis demonstrates that the data from SPRINT are discordant with the rest of the trials. In a sensitivity analysis with SPRINT removed, the RR for total mortality in the remaining 10 RCTs (N = 29,223) increased to RR 1.03 [0.92, 1.05]. Unfortunately, total serious adverse events were reported in only 3 of the 11 RCTs. In these 3 RCTs (N = 14,432), total serious adverse events were not decreased in the low BP target group, RR 1.03 [0.99, 1.08].

**Other non-Cochrane systematic reviews**
Systematic reviews that combine all RCTs comparing more intensive BP therapy are misleading and should not be used as evidence in favour of lower targets. These reviews include trials with markedly different targets, for example, a trial comparing a BP target of <150/85 with <180/105 mmHg.

**Conclusions**
- At the present time, lower BP targets (≤135/85 mmHg) have not been demonstrated to reduce mortality or total serious adverse events as compared with standard BP targets (≤140-160/90-100 mmHg).
- Careful analysis of the SPRINT trial reveals that benefits of a lower BP target in high-risk non-diabetic people do not outweigh harms.
- Critical appraisal of systematic reviews and clinical trial reports often leads to interpretation and conclusions different from initial impressions.

**References**